CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
TipRanks on MSN
Mixed options sentiment in Moderna with shares up 1.26%
Mixed options sentiment in Moderna (MRNA), with shares up 33c, or 1.26%, near $26.58. Options volume running well above average with 93k contracts ...
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.
New research shows Moderna and Pfizer’s mRNA vaccines may prime the immune system to attack cancer—even better than some ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...
Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 ...
Fintel reports that on October 23, 2025, Citigroup maintained coverage of Moderna (NasdaqGS:MRNA) with a Neutral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback